Dr. Mark R. Olsen, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Wisconsin School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,068
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: University of Wisconsin School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OK license 20723
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Francis Hospital, Inc Tulsa, OK
- Ascension St John Medical Center Tulsa, OK
- Saint Francis Hospital South, LLC Tulsa, OK
- Cherokee Nation W W Hastings Indian Hospital Tahlequah, OK
Medical groups
- Oklahoma Cancer Specialists and Research Institute, LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,068
- Services billed
- 214,991
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 24,750 | 32 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 15,911 | 176 |
| Injection, nivolumab, 1 mg | 14,860 | 30 |
| Injection, pembrolizumab, 1 mg | 12,000 | 34 |
| Injection, paclitaxel, 1 mg | 11,011 | 50 |
| Injection, granisetron, extended-release, 0.1 mg | 11,000 | 81 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 10,980 | 12 |
| Injection, aprepitant, 1 mg | 10,140 | 62 |
| Injection, oxaliplatin, 0.5 mg | 9,600 | 23 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,300 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxyurea Other prescribers in Tulsa, OK | 70 |
| Prednisone Other prescribers in Tulsa, OK | 60 |
| Ondansetron Odt (ondansetron) Other prescribers in Tulsa, OK | 58 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Tulsa, OK | 52 |
| Dexamethasone Other prescribers in Tulsa, OK | 51 |
| Letrozole Other prescribers in Tulsa, OK | 48 |
| Levofloxacin Other prescribers in Tulsa, OK | 42 |
| Revlimid (lenalidomide) | 41 |
| Prochlorperazine Maleate Other prescribers in Tulsa, OK | 39 |
| Abiraterone Acetate | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 27 payments worth $569 in total to this clinician.
| Daiichi Sankyo Inc. | $181 |
|---|---|
| Pfizer Inc. | $137 |
| AstraZeneca Pharmaceuticals LP | $64.67 |
| Beone Medicines USA, Inc. | $47.26 |
| Genzyme Corporation | $21.16 |
| Geron Corporation | $20.44 |
| Regeneron Healthcare Solutions, Inc. | $19.54 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.14 |
| Food and Beverage | $478 |
|---|---|
| Education | $90.23 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 12, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $30.65 |
| Pfizer Inc. Feb 7, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. May 27, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Jan 17, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Mar 10, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Pfizer Inc. May 27, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Pfizer Inc. Jan 17, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,217 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.